Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.
Amazon is the latest tech giant to consider expanding into healthcare, but details of the online retailer's plans are sketchy.
The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some high-profile attention for a batch of preliminary numbers suggesting a trend toward lower cardiovascular risks.
Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma giant painted in the numbers, completing the late-stage picture for a closely watched therapy that has the potential to rival the most successful drug franchises now on the market.
GlaxoSmithKline's vaccine candidate for the deadly Ebola virus is ready to roll in human trials.
President Obama highlighted a $78.9 million BRAIN Initiative project to improve service members' and veterans' health through the development of nano-scale electrical implants to modulate nerve signaling and record health biomarkers.
AB SCIEX and Dalton Pharma Services announced that they are joining forces on R&D of Antibody-Drug Conjugate analysis capabilities.
Plastic surgeons in India were able to convert CT scans of a three-year-old girl suffering with craniosynostosis into a physical replica using a 3-D printer. The realistic, life-size model was then used in practice runs of the surgery.
Advanced Catheter Therapies' venture capital funding round has been oversubscribed, reflecting investor interest in the company's Occlusion Perfusion Catheter for localized drug delivery in the peripheral vasculature.
The S-1 prominently features Civitas' successful Phase IIb study for an inhaled formulation of levodopa, a "rescue" treatment for Parkinson's patients.